Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

MedImmune Beats Estimates, Begins CAIV-T Phase III Study

Oct. 22, 2004

By Aaron Lorenzo

Positive Phase III CTLA4-Ig Data Bump Repligen's Stock

Oct. 22, 2004

By Aaron Lorenzo

MedImmune Beats Estimates, Begins CAIV-T Phase III Study

Oct. 22, 2004

By Aaron Lorenzo

Personalized Medicine Coalition Formed To Benefit Health Care

Oct. 21, 2004

By Aaron Lorenzo

Personalized Medicine Coalition Formed To Benefit Health Care

Oct. 21, 2004

By Aaron Lorenzo

CuraGen Trims Employees For Third Time In Two Years

Oct. 20, 2004

By Aaron Lorenzo

Neurocrine Files NDA For Immediate-Release Indiplon

Oct. 20, 2004

By Aaron Lorenzo

Neurocrine Files NDA For Immediate-Release Indiplon

Oct. 20, 2004

By Aaron Lorenzo

CuraGen Trims Employees For Third Time In Two Years

Oct. 20, 2004

By Aaron Lorenzo

Phase III Ceplene Miss Fallout Continues; Maxim Cuts Staff

Oct. 19, 2004

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....